Lysyl oxidase-like 3 mRNA expression indicates poor survival from oral squamous cell carcinoma  by Shieh, Tzong-Ming et al.
Journal of Dental Sciences (2011) 6, 205e209Available online at www.sciencedirect.com
journal homepage: www.e- jds.comORIGINAL ARTICLE
Lysyl oxidase-like 3 mRNA expression indicates poor
survival from oral squamous cell carcinomaTzong-Ming Shieh a, Shun-Yao Ko b,c, Shu-Shin Chang b,c, Kuo-Wei Chang d,e,
Yin-Hua Shih d, Chung-Ji Liu d,f,g*aDepartment of Dental Hygiene, School of Health Care, China Medical University, Taichung, Taiwan
bGraduate Institute of Medical Science, Chang Jung Christian University, Tainan, Taiwan
c Innovate Research Center of Medicine, Chang Jung Christian University, Tainan, Taiwan
d Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
eDepartment of Dentistry, Taipei Veterans General Hospital, Taipei, Taiwan
fOral and Maxillofacial Surgery, Taipei Mackay Memorial Hospital, Taipei, Taiwan
gMacKay Medical College, Taipei, Taiwan
Received 29 June 2011; accepted 26 September 2011
Available online 20 October 2011KEYWORDS
lysyl oxidase;
lysyl oxidase-like
protein 3;
oral squamous cell
carcinoma;
survival* Corresponding author. Department
Road, Taipei 10449, Taiwan.
E-mail address: cjliu@ms2.mmh.or
1991-7902/$36 Copyrightª 2011, Assoc
doi:10.1016/j.jds.2011.09.004Abstract Background/purpose: Oral squamous cell carcinoma (OSCC) is highly prevalent
worldwide. Lysyl oxidase (LOX) is an important enzyme that modulates the extracellular
matrix. The LOX superfamily contains LOX and LOX-like (LOXL) enzymes. The aim of the
present study was to determine the expressions of LOXL genes in OSCC.
Materials and methods: RT-PCR was performed to detect messenger (m)RNA expression of the
LOXL genes, LOX-L1, -L3, and -L4, in paired OSCC and non-cancerous matched tissues (NCMTs).
Results: Increased mRNA expressions of LOX-L1 and LOX-L3 in OSCC relative to NCMTs were
identified in 41% and 65% of OSCC samples, respectively. The normalized mRNA expression
of LOXL-3 was 1.11  0.15 in OSCC, which was significantly higher than 0.68  0.12 in NCMTs
(P Z 0.004). The increased expression of LOX-L3 was associated with worse survival of OSCC
patients (P Z 0.028).
Conclusion: The results indicated the frequent increase in LOX-L3 mRNA expression in OSCC,
and the value of LOX-L3 mRNA expression might have clinical uses in monitoring OSCC.
Copyright ª 2011, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.of Oral and Maxillofacial Surgery, Mackay Memorial Hospital, Number 92, Section 2, Chung Shan N
g.tw (C.-J. Liu).
iation for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1 Clinical parameters of OSCC.
Parameters Case (n Z 37)
Gender
Male 35
Female 2
Age (y)
Mean  SEM 51.4  0.8
Range 31e68
Location
Buccal 16
Non-buccal 21
Stage
IeIII 19
IV 18
Lymph node metastasis
Absence 20
Presence 17
Differentiation
Well 8
Moderate or poor 29
Areca use
Absence 9
Presence 27
Smoking
Absence 9
Presence 28
Alcohol use
Absence 18
Presence 19
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Lysyl oxidase (LOX) is a copper-dependent amine oxidase.
Activated LOX oxidatively deaminates the ε-amino group of
specific peptidyl lysine and hydroxylysine residues in
collagen, and of lysine in elastin, resulting in cross-linkages
and stabilization of collagen and elastin for extracellular
matrix (ECM) homeostasis.1,2 However, recent studies also
indicated that LOX can be translocated into nuclei, but its
function is unclear.3,4 The LOX superfamily includes LOX
and LOX-like (LOXL) proteins, which are encoded by LOXL
genes: LOX-L1e4. LOXL proteins also contain conserved
copper binding and catalytic domains at the COOH termini.
However, they might be functionally distinctive entities,
because they possess a longer and more complicated NH2-
terminal domain than LOX.1,2
LOX was found to be expressed in fibrogenesis areas in
breast carcinomas.5 Upregulation of LOX was reported to be
correlated with higher stages of renal cell cancers6; in
particular, LOX expression in humans increased the invasive
capacity of breast cancer cell lines in vitro.7 By contrast,
LOX was reported to suppress the growth of NIH3T3 cells
transformed by the ras oncogene.8 LOX was downregulated
in ras-transformed cells, but it was re-expressed in rever-
tants.8 Silencing of LOX or loss of LOX expression was
described in epithelial carcinogenesis.9,10 Immunoreactivity
of LOX in stroma was demonstrated in the periphery of oral
squamous cell carcinoma (OSCC) cell nests.11 A recent study
showed a remarkable reduction of LOX mRNA expression in
head and neck squamous cell carcinoma (HNSCC) cell lines
and tumor tissues. This might support the notion that LOX
acts as a tumor suppressor during tumorigenesis in HNSCC.12
However, recent studies showed an association between
LOX expression and tumorigenesis in HNSCC and OSCC.13,14
The contribution of LOXL to tumorigenesis is not clear.
Reports indicated that in addition to LOX metastatic breast
cancer cell lines expressed LOX-L1 and LOX-L2,5,7 which
suggests that LOXL enhances the malignancy of tumors.
Deletion of the LOX-L2 gene corresponded with decreased
cell adhesion.15 LOX-L2 was downregulated in HNSCC cell
lines but not in tumor tissues,12 whereas upregulation of
LOX-L4 was found in both HNSCC cell lines and tissues.16
Shieh et al13 showed the eminent increase of LOX-L2 in
areca-associated OSCC. Therefore, the pattern and preva-
lence of LOXL gene mRNA expressions in HNSCC and OSCC
are still controversial.
OSCC is the third most prevalent malignancy in devel-
oping countries with an unclear pathogenesis.17e19 The
present study comprehensively evaluated mRNA expres-
sions of LOXL genes in OSCC and corresponding non-
cancerous matched tissue (NCMT) pairs. We identified
that an increase in LOX-L3mRNA expression was frequent in
OSCC, and this event was associated with worse outcomes.
Materials and methods
Samples
OSCC and the paired NCMTs were sampled as approved by
an institutional review committee. Tissue samples were
immediately frozen in liquid nitrogen until use. A selectionprocess was performed on frozen sections to obtain 37
OSCC samples with more than 70% tumor cells, which was
required for the analysis.18 All OSCC patients were male,
except for two. Clinicopathological parameters, including
age, oral habits, lesion site, differentiation, lymph node
metastasis, and clinical stage, are given in Table 1.
RNA isolation
Total RNA was prepared from OSCC and NCMTs using a Tri-
reagent RNA isolation kit (Molecular Research Center, Cin-
cinnati, OH, USA). RNA was treated with DNase I (Stra-
tagene, La Jolla, CA, USA) to remove contaminating DNA.
Reverse-transcription polymerase chain reaction
(RT-PCR)
Two micrograms of total RNA were reverse-transcribed into
complementary (c)DNA using an oligo-dT(18) primer and
reverse transcriptase (Stratagene). cDNA equal to 0.5 mg of
total RNA was used to analyze target gene expressions by
a semiquantitative RT-PCR using the primers in Table 2.
Amplification of these genes was performed with 25e35
cycles at 94 C for 1 minute, 55e58 C for 1 minute, and
72 C for 1 minute. The cycle number of the PCR was
Table 2 Oligo primers used in the present study.
Gene Primer sequence Annealing temp. (C) Amplicon size (bp)
LOX-L1 Sense: 50-acttggtcccagaccccaac-30
Antisense: 50-agcacccgcacatcgtagtc-30
56 145
LOX-L3 Sense: 50-aagcaacaacagtcgaagcc-30
Antisense: 50-tccagagcagcgaacttcac-30
56 252
LOX-L4 Sense: 50-atgagaatgctgctgctgtc-30
Antisense: 50-aaccaggtttccttgtaggc-30
58 235
GAPDH Sense: 50-tggtatcgtggaaggactcatgac-30
Antisense: 50-atgccagtgagcttcccgttcagc-30
55 189
LOXL in oral carcinoma 207optimized by pilot studies to assure that the amplification
was within the logarithmic phase. PCR products were
resolved on a 2% agarose gel and visualized by an imaging
system (Viber Lourmat, Marne La Valle, France). Densities
of the signals were measured by a densitometer (Amer-
sham, Piscataway, NJ, USA). Amplification of GAPDH served
as the internal control. The messenger (m)RNA expression
in LOXL genes was normalized by the relative intensity of
signals from tested genes versus GAPDH. An OSCC showing
a substantial increase ( 1.3-fold) on the tested gene/
GAPDH ratio, compared with the corresponding NCMT, was
defined as having increased mRNA expression. An OSCC
exhibiting a ratio of 0.7e1.3 compared with NCMT was
defined as being equal in mRNA expression for the sample
pairs. The remaining OSCCs were defined as having
decreased mRNA expression in the tested gene. Three
independent PCRs were performed to validate the repro-
ducibility of the analysis. Cases exhibiting inconsistent
results were excluded from the final analysis.
Statistical analysis
The statistical correlation between each group was analyzed
by a t test, logistic regression, or Fisher’s exact test. Time-
to-mortality curves were estimated by the KaplaneMeier
method and compared using the long-rank test. A P value
<0.05 was considered statistically significant.Figure 1 (A) RT-PCR analysis of representative tissue pairs for LO
LOX-L3 gene. N Z NCMT; T Z OSCC.Results
Subjects
The ages of the patients ranged from 31 to 68 years
(meanZ 51 years). The most common primary site was the
buccal mucosa (43%, 16 cases) (Table 1). Regarding the
histopathological grade, 21% (eight cases) of OSCCs were
well-differentiated. Forty-six percent (17 cases) of patients
presented with lymph node metastasis. Forty-nine percent
(18 cases) of patients had a stage IV tumor. The median
follow-up period was 18.5 months.mRNA expression of LOXL genes
The RT-PCR analysis was performed on 37 OSCC/NCMT
pairs. Sample pairs exhibiting inconsistent PCR results were
eliminated; thus, there were 37, 34, and 33 sample pairs
available for the LOX-L1, -L3, and -L4 analyses, respec-
tively. Representative results of sample pairs exhibiting
distinctive mRNA expression patterns of LOXL genes are
shown in Fig. 1. There were 41%, 65%, and 31% of OSCCs
that exhibited increases in LOX-L1, -L3, and -L4 mRNA
expressions relative to NCMTs, respectively (Fig. 2). The
expression profile of LOXL genes in sample pairs is plotted
in Fig. 3. A statistically significant difference in LOX-L3XL genes. (B) RT-PCR analysis of representative tissue pairs for
LOX-L1 LOX-L3 LOX-L4
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Figure 2 The percentage of tissue exhibiting increased
(empty box), equal (shadow box), or decreased (black box)
mRNA expression of LOXL genes in OSCC. Note that around two-
thirds of OSCC had LOX-L3 mRNA expression increase relative
to the corresponding NCMT.
Table 3 mRNA expression of LOXL genes in tissue pairs.a
Gene n NCMT OSCC P
LOX-L1 37 0.67  0.07 0.77  0.07 0.11
LOX-L3 34 0.68  0.12 1.11  0.15 0.004
LOX-L4 33 0.64  0.09 0.66  0.10 0.79
a Paired t test.
208 T.-M. Shieh et almRNA expression (0.68  0.12 vs. 1.11  0.15, P Z 0.004)
between NCMTs and OSCC was noted (Table 3).
Concordance of LOXL gene mRNA expressions
A regression analysis was used to analyze mRNA expressions
of LOXL genes in OSCC, and it was normalized with the
respective NCMTs to identify their relationship. No signifi-
cant concordance in the mRNA expressions of LOXL genes
was found (detailed analysis not shown).
Correlation with clinical parameters
The statistical analysis did not show a correlation between
the increase in mRNA expression and clinicopathological
characteristics of subjects for LOX-L1, -L3, and -L4
(detailed analysis not shown). There was a significant
association of a worse prognosis with an increase in LOX-L3
mRNA expression (P Z 0.028) with a hazard ratio of 3.89
(Fig. 4).
Discussion
LOX and LOXL are enzymes that can modulate the ECM and
are important for homeostasis of collagen and elastin; novel
functions for differentiation and cell proliferation wereNCMT OSCC
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Figure 3 The distribution of normalized mRNA expression lev
summarized in Table 3.proposed.1,2 LOX overexpression facilitates metastasis in
some cell lines,7 whereas LOX transfection can abrogate
Ras-mediated transformation.8 Both up- and down-
regulation of LOX and LOXL were observed in malignancies.
This has caused controversies regarding their roles in path-
ogenesis. This study showed an increase in LOX-L3 mRNA
expression in OSCC relative to NCMTs (Fig. 3). As stromal
cells also generate LOX, this might bias the evaluation of
LOXL gene expressions in tumor tissues. However, this is
unlikely to be a major issue in this study, as stromal or
inflammatory cells accounted for < 30% of total cells in the
tumor specimens studied. It was interesting to note the
disconcordance in LOXL gene expressions and the absence
of preferential alterations in certain samples (representa-
tive cases in Fig. 1). The fact suggests that different
elements are involved in regulating LOXL gene expression.
The role of LOX-L3 in the neoplastic process has not yet
been addressed. In this study, we demonstrated for the first
time a significant increase in mRNA expression of LOX-L3 in
OSCC compared with NCMTs. Notably, the increased LOX-L3
mRNA expression was associated with a worse prognosis of
patients (Fig. 4). It was reported that splicing of LOX-L3
could generate additional variants with unique functions.2
Nuclear localization of LOX-L3 in kidney and liver cells
further suggests that LOX-L3 may have a distinctive func-
tion.2 As LOX-L3 mRNA expression was not related to lymph
node metastasis, other than tumor invasion, the involve-
ment of LOX-L3 in chemoresistance or cancer cell prolif-
eration should be addressed. In the future, a therapeutic
strategy targeting LOX-L3might be available to improve the
survival rate of related OSCC patients. The LOX-L1 protein
was identified in active fibrotic diseases and in an early
stromal reaction with breast cancer.5
A recent study indicated that the downregulation of
LOX-L1 in skin and heart of mice may produce the rough
coat (rc) phenotype from a spontaneous mutation.20
However, the oncogenic potential of LOX-L1 was rarelyL
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Figure 4 Increase of LOX-L3 mRNA expression and the worse
survival (KaplaneMeier survival analysis). Approximately 55%
and 92% of subjects with OSCC displaying increased LOX-L3
mRNA expression and opposite LOX-L3 status, respectively,
were alive by the end of follow-up. CI Z confidence interval;
HR Z hazard ratio.
LOXL in oral carcinoma 209defined. We identified no significant change in LOX-L1
mRNA expression levels between OSCC and paired NCMTs
(Table 3). As the increased LOX-L1 mRNA expression was
associated with lymph node metastasis of OSCC (Table 1), it
was thought to contribute to the adhesion or migration of
oral keratinocytes through interacting with the ECM.5
With a differential display and subsequent character-
ization, Holtmeier et al16 found a moderate to high level of
LOX-L4 mRNA expression in around one-third of HNSCC cell
lines and two-thirds of HNSCC tumor tissues analyzed. We
found no remarkable change in LOX-L4 mRNA expression in
OSCC/NCMT pairs (Figs. 3 and 4, Table 3). Except for racial
and site-specific differences that might underlie the
disparities, there is no commercial LOXL antibody available
for further investigation of possible discrepancies. Overall,
this study profiled mRNA expressions of LOXL genes, and
evidenced the prominent upregulation of LOX-L3 during
oral tumorigenesis. These findings together with the iden-
tification of increases in LOX and LOX-L2 expressions in
areca-associated OSCC may substantiate the tumorigenic
roles of LOX and some LOX-L members for oral carcino-
genesis in areca chewers.13 In the future, the protein
expression, activity, and function of such LOX family
members should be further investigated to highlight the
roles of LOXL during the neoplastic process.
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